Kazmira Launches Prescription-Only CBD Pharmacy

Kazmira presents a submissive, prescription-only model of cannabis pharmacy against the stricter U.S. cannabis laws.

Kazmira Therapeutics has announced the launch of Kazmira Pharmacy, positioning it as the first-of-its-kind, prescription-only cannabinoid pharmacy in the United States. The accredited LegitScript 503A compounding pharmacy specializes in the production of ultra-pure cannabidiol with no traces of tetrahydrocannabinol, which is the intoxicating product that hemp contains.

The project is set to elevate CBD from a loosely regulated over-the-counter medication to evidence-based, pharmacy-dispensed medicine as described by the co-founder and co-CEO Priyanka Sharma. She witnessed that medical practitioners can now order customized treatment that is based on the specific requirements of the patients, enhancing the clinical supervision and patient safety.

Studies of ultrapure CBD have investigated its use in the treatment of pain, anxiety, and substance abuse. Sharma stressed that prescription-only CBD could provide an option to those patients who do not have a favorable response rate to conventional treatment. It is also heavily regulated due to increased scrutiny by the administration, as a December 2025 executive order moved cannabis back to Schedule III, which effectively limits over-the-counter products with more than established limits of THC.

Gautham Oroskar, a medicine consultant, emphasized that withdrawing the issue of intoxication and drug testing enables doctors to treat CBD as any other form of therapeutic drug. Kazmira Pharmacy has an intention to launch in over 20 states by the year 2026, starting with the State of Colorado. They will closely work with the State Pharmacy Boards in order to 100 percent comply with the regulations.